SLS Stock Analysis: Sellas Life Sciences | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 2.946m USD | 12M Return: 522.1% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 85.9M
Qual. Beats: 0
Qual. Beats: 0
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
SELLAS Life Sciences Group is a late-stage clinical biopharmaceutical company developing novel cancer therapeutics, with its lead candidates being galinpepimut-S (GPS), a peptide immunotherapy targeting the Wilms tumor 1 (WT1) antigen, and SLS009 (tambiciclib), a selective CDK9 inhibitor. The company operates in the high-risk, capital-intensive biotech model typical of clinical-stage oncology developers, where value is driven primarily by pipeline progress, clinical trial readouts, and partnership milestones rather than recurring product revenue. SELLAS has established strategic collaborations with Merck & Co. to evaluate GPS in combination with pembrolizumab across multiple cancer indications, with GenFleet Therapeutics for the development of GFH009, and with Memorial Sloan Kettering Cancer Center for WT1 peptide vaccine technology.
- GPS Phase 3 AML trial data readout expected this quarter
- Merck collaboration advances GPS-pembrolizumab combination into multiple cancer indications
- Cash burn and dilution risk as SLS009 CDK9 trials expand
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.25 > 0.02 and ΔFCF/TA 71.77 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.25 > 3% & CFO -28.2m > Net Income -29.5m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 17.22 > 1.5 & < 3 |
| Outstanding Shares: last quarter (172.5m) vs 12m ago 96.54% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.92 (Total Current Assets 111.2m - Total Current Liabilities 6.46m) / Total Assets 114.2m |
| B: -2.48 (Retained Earnings -283.4m / Total Assets 114.2m) |
| C: -0.42 (EBIT TTM -31.5m / Avg Total Assets 74.6m) |
| D: 15.88 (Book Value of Equity 107.4m / Total Liabilities 6.76m) |
| Altman-Z'' = 11.76 = AAA |
As of July 08, 2026, the stock is trading at USD 13.50 with a total of 8,129,178 shares traded. Over the past week, the price has changed by -12.62%, over one month by +69.17%, over three months by +199.33% and over the past year by +522.12%.
Current recommended Stop Loss: 11.90 (which is 11.9% or 1.2 ATR below the current price).
Sellas Life Sciences has received a consensus analysts rating of 4.67. Therefore, it is recommended to buy SLS.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 10 | -25.9% |
P/S = 26.8951
P/B = 24.256
Revenue TTM = 0.0 USD
EBIT TTM = -31.5m USD
EBITDA TTM = -31.5m USD
Long Term Debt = 309k USD (estimated: total debt 871k - short term 562k)
Short Term Debt = 562k USD (from shortTermDebt, last quarter)
Debt = 871k USD (from shortLongTermDebtTotal, last quarter) (leases 871k already included)
Net Debt = -106.3m USD (calculated: Debt 871k - CCE 107.2m)
Enterprise Value = 2.84b USD (2.95b + Debt 871k - CCE 107.2m)
Interest Coverage Ratio = unknown (Ebit TTM -31.5m / Interest Expense TTM 0.0)
EV/FCF = -100.8x (Enterprise Value 2.84b / FCF TTM -28.2m)
FCF Yield = -0.99% (FCF TTM -28.2m / Enterprise Value 2.84b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 24.87 (Enterprise Value 2.84b / Total Assets 114.2m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 871k)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -24.9m (EBIT -31.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 17.22 (Total Current Assets 111.2m / Total Current Liabilities 6.46m)
Debt / Equity = 0.01 (Debt 871k / totalStockholderEquity, last quarter 107.4m)
Debt / EBITDA = 3.38 (negative EBITDA) (Net Debt -106.3m / EBITDA -31.5m)
Debt / FCF = 3.78 (negative FCF - burning cash) (Net Debt -106.3m / FCF TTM -28.2m)
Total Stockholder Equity = 62.5m (last 4 quarters mean from totalStockholderEquity)
RoA = -39.50% (Net Income -29.5m / Total Assets 114.2m)
RoE = -47.12% (Net Income TTM -29.5m / Total Stockholder Equity 62.5m)
RoCE = -50.08% (EBIT -31.5m / Capital Employed (Equity 62.5m + L.T.Debt 309k))
RoIC = -22.95% (negative operating profit) (NOPAT -24.9m / Invested Capital 108.3m)
WACC = 8.70% (E(2.95b)/V(2.95b) * Re(8.70%) + D(871k)/V(2.95b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 8.70% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 115.0%
[DCF] Fair Price = unknown (Cash Flow -28.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.41 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.05 | Chg30d=+25.04% | Revisions=+0% | Analysts=2
EPS next Quarter (2026-09-30): EPS=-0.06 | Chg30d=+24.97% | Revisions=+0% | Analysts=2
EPS current Year (2026-12-31): EPS=-0.21 | Chg30d=+25.87% | Revisions=+40% | GrowthEPS=+16.0% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.15 | Chg30d=+16.67% | Revisions=+17% | GrowthEPS=+28.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +30% (up=5, down=2)